Expanding Precision Oncology With Targeted Immunotherapy

Dr. Pedro Barata and Dr. Bridget Keenan discuss the innovative bioengineering allowing clinicians to target historically "immune-cold" tumors, the logistical evolution of bringing bispecific therapies safely into outpatient community clinics, and the complex future of predictive biomarkers and resistance mechanisms.

LINK TO FULL TRANSCRIPT